Switzerland-based Abionic is hoping to accelerate the turn-around time for diagnostics with its AbioSCOPE point-of-care diagnostics platform. Abionic’s nanofluidic technology is capable of measuring 14 parameters from just a drop of blood in a matter of minutes.
With Theranos and its exposure as a fraud still fresh in the minds of investors and other medtech stakeholders, Abionic is keen to set itself apart, with a